uniQure Extends Cash Runway to 2029 Amid Ongoing FDA Talks for Huntington's

uniQure N.V. (NASDAQ:QURE) has reported its full-year 2025 financial results, highlighting a robust cash position that significantly de-risks its operations through the end of the decade. With approximately $622.5 million in cash, cash equivalents, and investment securities as of December 31, 2025, the company has extended its operational runway into the second half of 2029. This financial stability is a critical asset in the capital-intensive gene therapy sector, providing uniQure with the flexibility to navigate complex regulatory pathways and advance its multi-asset clinical pipeline without the immediate pressure of dilutive financing.

The central focus for investors remains the regulatory trajectory of AMT-130, uniQure’s investigational gene therapy for Huntington’s disease. Following a Type A meeting with the U.S. Food and Drug Administration (FDA), the company confirmed that while 36-month clinical data has shown compelling evidence of disease modification, a definitive alignment on an approval pathway has not yet been reached. Type A meetings are typically reserved for stalled programs or dispute resolutions, suggesting that the FDA may be requiring more traditional Phase III evidence than the accelerated pathway uniQure might have initially targeted. The company is now evaluating Phase III development considerations and plans to request a follow-up Type B meeting in the second quarter of 2026 to further refine the clinical strategy.

“

With approximately $622.5 million in cash, cash equivalents, and investment securities as of December 31, 2025, the company has extended its operational runway into the second half of 2029.

The lack of immediate regulatory alignment for AMT-130 underscores the high bar the FDA maintains for gene therapies in neurodegenerative conditions with complex pathologies. Huntington’s disease, characterized by the progressive loss of motor and cognitive function, has historically been a graveyard for drug development. uniQure’s 36-month data, which the company describes as durable and dose-dependent, represents some of the most significant long-term evidence in the field. However, the FDA’s cautious stance likely reflects broader concerns regarding surrogate endpoints and the durability of effect in larger patient populations. This regulatory friction is not unique to uniQure; other gene therapy pioneers have faced similar challenges in translating early-stage clinical success into a clear path for commercialization.